Investment Thesis
C4 Therapeutics demonstrates critically weak fundamental operations with only $6.2M in revenue growing at a negligible 1.0% YoY, paired with severe operating losses of -$27.8M generating -451.6% operating margin. Despite a fortress balance sheet with $61.3M cash and zero debt, the company faces acute cash burn of approximately $30M per period, providing minimal runway and signaling fundamental commercial or product viability challenges that balance sheet strength cannot offset.
Strengths
- Strong balance sheet with $234.2M stockholders equity and zero long-term debt eliminating solvency risk
- Excellent liquidity position with 9.0x current ratio and sufficient cash reserves for near-term operations
- No debt burden reducing financial leverage risk and providing flexibility for strategic options
Risks
- Critically low revenue of $6.2M with near-zero growth rate (+1.0% YoY) suggesting failed commercial execution or product rejection
- Severe operating losses of -$27.8M generating unsustainable -451.6% operating margin indicating business model dysfunction
- Negative free cash flow burn rate of -$30.0M per period exhausting capital reserves with limited runway despite strong initial balance sheet
Key Metrics to Watch
- Revenue growth acceleration - current 1% growth is unacceptable for staged biotech; track for inflection or further decline
- Cash balance runway - monitor depletion timeline at current -$30M burn rate; assess need for capital raise
- Operating loss trajectory - track whether -$27.8M operating loss stabilizes or worsens in coming periods
Financial Metrics
Revenue
6.2M
Net Income
-25.1M
EPS (Diluted)
$-0.20
Free Cash Flow
-30.0M
Total Assets
328.9M
Cash
61.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-451.6%
Net Margin
-408.5%
ROE
-10.7%
ROA
-7.6%
FCF Margin
-487.8%
Balance Sheet & Liquidity
Current Ratio
9.00x
Quick Ratio
9.00x
Debt/Equity
0.00x
Debt/Assets
28.8%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T07:12:12.199823 |
Data as of: 2026-03-31 |
Powered by Claude AI